FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580515099> ?p ?o ?g. }

• W2580515099 abstract "Abstract We added Sirolimus to an established conditioning regimen in an attempt to optimize engraftment and anti-tumor effects while minimizing GVHD. 55 patients patients with advanced hematological malignancies (median age 60) received cyclophosphamide (1gm/m2 days −7 and −6) and fludarabine (25mg/m2 days −7 through −3) prior to peripheral blood cell (51 patients) or marrow (4 patients) transplant. All received sirolimus with tacrolimus, both adjusted to 5–15ng/ml, and methotrexate (5mg/m2 days 1,3, 6) immunoprophyllaxis. Tacrolimus was tapered from days 30–45 in matched siblings (Msib -12 patients) and days 40–100 in (most) alternative donor recipients (AltD- unrelated donor or 5/6 matched related cells - 43 patients) without acute GVHD. Median follow-up is 313 days in AltD patients and 337 days for Msib patients. All Msib cells engrafted, whereas 3/43 AltD recipients showed primary graft failure or secondary graft failure (1/43). Msib recipients engrafted more rapidly than those with AltD transplants (p&lt;0.01). For AltD recipients, the CD34 dose had a positive significant effect on donor engraftment - chimerism (p&lt;0.05 for all points up to D100). Median overall and disease free survival was 287 and 230 days respectively for AltD patients and 303 and 167 days for Msib recipients. Amongst AltD patients, 17/43 survive progression free at D114-1167 (median D416), while in MSib patients only 1/12 survives progression free (p=0.0023 ). Two additional patients are disease free after donor lymphocytes (DLI) or withdrawal of immunosuppression in each group. No patient in the Msib group had transplant related mortality (TRM), but in the AltD group there were nine TRMs, including 7 from GVHD (NS). Multivariate analysis showed CD34 dose and donor types had no significant effect on development of progressive disease (PD). However, in general the odds ratio of any PD decreased exponentially as the level of chimerism increased. For example, at D100 the odds of developing PD decreased by 0.699 times when the level of chimerism increased by 0.1. Multinomial logit analysis showed that compared to GVHD death, the odds ratios for PD death decreased exponentially as the level of chimerism increased. In this series of patients with advanced hematological malignancy, Alternative donor cells provided a higher probability of control of disease, albeit with a trend to higher TRM. Higher CD34 cell doses were associated with improved donor engraftment (chimerism) in AltD recipients. For AltD recipients, risk of PD was reduced by increasing donor chimerism, but increasing chimerism is associated with increased risk of death from GVHD. Efforts to improve control of malignancy via more rapid engraftment of donor cells must be tempered with concern regarding potentially severe GVHD. Figure Figure" @default.
• W2580515099 created "2017-02-03" @default.
• W2580515099 creator A5004302802 @default.
• W2580515099 creator A5030667484 @default.
• W2580515099 creator A5041616645 @default.
• W2580515099 creator A5059838967 @default.
• W2580515099 creator A5076439728 @default.
• W2580515099 date "2005-11-16" @default.
• W2580515099 modified "2023-10-18" @default.
• W2580515099 title "Non-Myeloablative Hematopoietic Transplant with Sirolimus Immunosuppression: Determinants of Outcome." @default.
• W2580515099 doi "https://doi.org/10.1182/blood.v106.11.5462.5462" @default.
• W2580515099 hasPublicationYear "2005" @default.
• W2580515099 type Work @default.
• W2580515099 sameAs 2580515099 @default.
• W2580515099 citedByCount "0" @default.
• W2580515099 crossrefType "journal-article" @default.
• W2580515099 hasAuthorship W2580515099A5004302802 @default.
• W2580515099 hasAuthorship W2580515099A5030667484 @default.
• W2580515099 hasAuthorship W2580515099A5041616645 @default.
• W2580515099 hasAuthorship W2580515099A5059838967 @default.
• W2580515099 hasAuthorship W2580515099A5076439728 @default.
• W2580515099 hasConcept C126322002 @default.
• W2580515099 hasConcept C141071460 @default.
• W2580515099 hasConcept C2776694085 @default.
• W2580515099 hasConcept C2776755627 @default.
• W2580515099 hasConcept C2777921159 @default.
• W2580515099 hasConcept C2779263901 @default.
• W2580515099 hasConcept C2780007613 @default.
• W2580515099 hasConcept C2780252810 @default.
• W2580515099 hasConcept C2781059491 @default.
• W2580515099 hasConcept C2781413609 @default.
• W2580515099 hasConcept C2909675724 @default.
• W2580515099 hasConcept C2911091166 @default.
• W2580515099 hasConcept C71924100 @default.
• W2580515099 hasConcept C90924648 @default.
• W2580515099 hasConceptScore W2580515099C126322002 @default.
• W2580515099 hasConceptScore W2580515099C141071460 @default.
• W2580515099 hasConceptScore W2580515099C2776694085 @default.
• W2580515099 hasConceptScore W2580515099C2776755627 @default.
• W2580515099 hasConceptScore W2580515099C2777921159 @default.
• W2580515099 hasConceptScore W2580515099C2779263901 @default.
• W2580515099 hasConceptScore W2580515099C2780007613 @default.
• W2580515099 hasConceptScore W2580515099C2780252810 @default.
• W2580515099 hasConceptScore W2580515099C2781059491 @default.
• W2580515099 hasConceptScore W2580515099C2781413609 @default.
• W2580515099 hasConceptScore W2580515099C2909675724 @default.
• W2580515099 hasConceptScore W2580515099C2911091166 @default.
• W2580515099 hasConceptScore W2580515099C71924100 @default.
• W2580515099 hasConceptScore W2580515099C90924648 @default.
• W2580515099 hasLocation W25805150991 @default.
• W2580515099 hasOpenAccess W2580515099 @default.
• W2580515099 hasPrimaryLocation W25805150991 @default.
• W2580515099 hasRelatedWork W1967399987 @default.
• W2580515099 hasRelatedWork W2067922960 @default.
• W2580515099 hasRelatedWork W2080813773 @default.
• W2580515099 hasRelatedWork W2093877097 @default.
• W2580515099 hasRelatedWork W2123622776 @default.
• W2580515099 hasRelatedWork W2125886803 @default.
• W2580515099 hasRelatedWork W2276676914 @default.
• W2580515099 hasRelatedWork W2373667423 @default.
• W2580515099 hasRelatedWork W3032430015 @default.
• W2580515099 hasRelatedWork W4289527905 @default.
• W2580515099 isParatext "false" @default.
• W2580515099 isRetracted "false" @default.
• W2580515099 magId "2580515099" @default.
• W2580515099 workType "article" @default.